Cyclacel Pharmaceuticals (STU:UXI) Tax Provision : €2.80 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Tax Provision?

Cyclacel Pharmaceuticals's tax provision for the three months ended in Mar. 2024 was €1.25 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was €2.80 Mil.

Cyclacel Pharmaceuticals Tax Provision Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Tax Provision Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

1.17

1.02

3.30

4.45

2.75

Cyclacel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															1.23	0.54	0.63	0.39	1.25

Cyclacel Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.80 Mil.

Cyclacel Pharmaceuticals (STU:UXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA CYCC:USA

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines